【2022 ASCO】Ascentage Pharma selected for seven clinical progresses, and multiple pipelines go hand in hand

Ascentage Pharma (6855.
HK), a leading biopharmaceutical company dedicated to the development of innovative drugs in the therapeutic areas of oncology, hepatitis B and aging-related diseases, announced today that a total of seven clinical studies of the company have been selected for the 2022 American Society of Clinical Oncology (American Society of Clinical Oncology).
ASCO) annual meeting, involving the third-generation tyrosine kinase inhibitor (TKI) orebatinib (HQP1351), Bcl-2 inhibitor APG-2575, MDM2-p53 inhibitor APG-115, ALK inhibitor APG- 2449 and five original research varieties of Bcl-2/Bcl-xL inhibitor APG-1252
.
The annual ASCO annual meeting is the most important and authoritative academic exchange event in the global oncology field, and will showcase the current international cutting-edge clinical oncology scientific research achievements and tumor treatment technologies
.
This ASCO annual meeting will be held online and offline at the McCormick Convention Center in Chicago from June 3 to 7 (US local time)
.
Zhai Yifan, Chief Medical Officer of Ascentage Pharma, said: "This will be the fifth consecutive year Ascentage Pharma has appeared at ASCO, and I am delighted to showcase our multiple clinical progress, which further demonstrates the company's global innovation and development capabilities
.
Further demonstration of the relevant experimental data of the apoptotic varieties APG-2575 and APG-115, which is expected to be the first domestic third-generation ALK inhibitor APG-2449, the clinical data will be disclosed for the first time.
The clinical progress of intestinal stromal tumor (GIST) will also be announced for the first time
.
We look forward to sharing more detailed data with you during the follow-up meeting
.
In the future, Ascentage will further accelerate the global clinical development and bring more information to patients as soon as possible.
Multiple treatment options
.
" Ascentage Pharma will present seven latest clinical trial progress at this ASCO Annual Meeting including: Orebatinib (HQP1351): Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI -) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).
Orebatinib (HQP1351) in tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase-deficient gastrointestinal stromal tumors Demonstrated good antitumor activity in patients with SDH-deficient GIST: Poster Discussion APG-2575: A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).